Samantha Semenkow
Stock Analyst at Citigroup
(0.78)
# 3,626
Out of 4,818 analysts
42
Total ratings
27.27%
Success rate
-23.35%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Samantha Semenkow
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARGX argenx SE | Maintains: Buy | $681 → $796 | $600.51 | +32.55% | 5 | Apr 17, 2025 | |
| BIOA BioAge Labs | Maintains: Neutral | $7 → $5 | $4.20 | +19.05% | 3 | Mar 24, 2025 | |
| SLRN Acelyrin | Maintains: Neutral | $6 → $3 | $2.17 | +38.25% | 2 | Jan 7, 2025 | |
| VYGR Voyager Therapeutics | Initiates: Buy | $12 | $3.53 | +239.94% | 1 | Dec 2, 2024 | |
| ALLO Allogene Therapeutics | Maintains: Buy | $7 → $8 | $1.57 | +409.55% | 2 | Aug 9, 2024 | |
| CPRX Catalyst Pharmaceuticals | Maintains: Buy | $27 → $31 | $23.19 | +33.68% | 2 | Aug 9, 2024 | |
| SANA Sana Biotechnology | Maintains: Buy | $8 → $15 | $1.77 | +749.86% | 2 | Aug 9, 2024 | |
| SNSE Sensei Biotherapeutics | Reinstates: Buy | $4 | $0.38 | +955.41% | 2 | Jun 3, 2024 | |
| LRMR Larimar Therapeutics | Maintains: Buy | $10 → $14 | $2.37 | +490.72% | 6 | May 22, 2024 | |
| PRME Prime Medicine | Upgrades: Buy | $10 | $1.75 | +471.43% | 2 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $15 | $1.61 | +831.68% | 4 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $12 | $4.99 | +140.72% | 2 | Apr 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $26 → $30 | $1.28 | +2,243.75% | 2 | Apr 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $72 | $39.50 | +82.28% | 1 | Dec 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $33 → $50 | $15.09 | +231.35% | 3 | Sep 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $60 → $56 | $20.17 | +177.71% | 3 | Aug 9, 2023 |
argenx SE
Apr 17, 2025
Maintains: Buy
Price Target: $681 → $796
Current: $600.51
Upside: +32.55%
BioAge Labs
Mar 24, 2025
Maintains: Neutral
Price Target: $7 → $5
Current: $4.20
Upside: +19.05%
Acelyrin
Jan 7, 2025
Maintains: Neutral
Price Target: $6 → $3
Current: $2.17
Upside: +38.25%
Voyager Therapeutics
Dec 2, 2024
Initiates: Buy
Price Target: $12
Current: $3.53
Upside: +239.94%
Allogene Therapeutics
Aug 9, 2024
Maintains: Buy
Price Target: $7 → $8
Current: $1.57
Upside: +409.55%
Catalyst Pharmaceuticals
Aug 9, 2024
Maintains: Buy
Price Target: $27 → $31
Current: $23.19
Upside: +33.68%
Sana Biotechnology
Aug 9, 2024
Maintains: Buy
Price Target: $8 → $15
Current: $1.77
Upside: +749.86%
Sensei Biotherapeutics
Jun 3, 2024
Reinstates: Buy
Price Target: $4
Current: $0.38
Upside: +955.41%
Larimar Therapeutics
May 22, 2024
Maintains: Buy
Price Target: $10 → $14
Current: $2.37
Upside: +490.72%
Prime Medicine
May 16, 2024
Upgrades: Buy
Price Target: $10
Current: $1.75
Upside: +471.43%
May 9, 2024
Maintains: Buy
Price Target: $16 → $15
Current: $1.61
Upside: +831.68%
Apr 8, 2024
Maintains: Buy
Price Target: $9 → $12
Current: $4.99
Upside: +140.72%
Apr 4, 2024
Maintains: Buy
Price Target: $26 → $30
Current: $1.28
Upside: +2,243.75%
Dec 8, 2023
Initiates: Buy
Price Target: $72
Current: $39.50
Upside: +82.28%
Sep 27, 2023
Maintains: Buy
Price Target: $33 → $50
Current: $15.09
Upside: +231.35%
Aug 9, 2023
Maintains: Buy
Price Target: $60 → $56
Current: $20.17
Upside: +177.71%